GlassScriptPhysician profile
Nathan M Kaller
NPI 1104230366
$2,480.44
in general payments reported to CMS, 2019-2025
38 companies · $68.17 in 2025
The $68.17 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $388 · 2021: $517 · 2022: $495 · 2023: $148 · 2024: $516 · 2025: $68.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $731.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $291.83 | 2019-2024 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $202.33 | 2019-2022 | |
| Lilly USA, LLC | $159.66 | 2020-2022 | |
| Abbott Laboratories | $154.65 | 2022-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $145.37 | 2019-2021 | |
| Antares Pharma, INC. | $126.59 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Inspire Medical Systems, INC. | $121.40 | 2024-2025 | Inspire |
| Pfizer INC. | $116.86 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $96.88 | 2019-2021 | |
| Insulet Corporation | $90.88 | 2023-2024 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $90.01 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.88 | 2021-2024 | Ofev |
| Sanofi-Aventis U.S. LLC | $67.13 | 2021-2023 | |
| Amgen INC. | $61.55 | 2020-2023 | Otezla, Repatha |
| Tandem Diabetes Care, INC. | $61.50 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Kaller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.